This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Cambridge, UK, 28 October 2021: Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million (circa £30 million) investment round. The round was led by Sofinnova Partners (Paris, France) and Redmile Group (San Francisco, USA) co-investing on equal terms.
This chart shows the patent expirations for ointment dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from…. The post Ointment dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.
By reader request, we present below a channel flow chart illustrating the buy-and-bill process for provider-administered drugs. This chart complements Follow the Dollar: The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-name Drugs. To further help you understand this channel, I have also included a brief video to explain the buy-and-bill system.
– Presbyopia, or age-related blurry near vision, is a common, progressive condition that reduces the eye’s ability to focus on near objects, affecting most adults over the age 40 – Phase 3 clinical studies demonstrated VUITY works in as early as 15 minutes and lasts for up to 6 hours, as measured on day 30, to improve near and intermediate vision without impacting distance vision – Allergan, an AbbVie company, continues legacy of eye care innovation with VUITY, a first-of
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Highly consistent and scalable supply of lab grown human skeletal muscle cells provide an effective and biologically relevant tool for research and drug development in conditions as diverse as metabolic and muscle diseases and ageing.
This chart shows the drugs with the most patents in Luxembourg. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Luxembourg? appeared first on DrugPatentWatch - Make Better Decisions.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
This chart shows the drugs with the most patents in Luxembourg. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Luxembourg? appeared first on DrugPatentWatch - Make Better Decisions.
Today’s guest post comes from Megan Marchal, Clinical Pharmacist at CoverMyMeds. Megan shares the story of Sophia Garland, a young professional who is living with and learning to manage a chronic medical condition that requires specialty medication. To learn more about technology and access to specialty medications, read the CoverMyMeds Medication Access Report: Complex Care & Specialty Edition.
Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine kinase inhibitor (TKI) treatments 1 In the pivotal Phase III ASCEMBL trial, Scemblix demonstrated significant and clinically meaningful superiority in major molecular response (MMR) rate vs.
In this post we explore how using a range of translational preclinical models can be used to accelerate the discovery and validation of predictive biomarkers, with the goal of de-risking drug development to increase the likelihood of clinical success for therapeutic candidates.
This chart shows the drugs with the most patents in Chile. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Chile? appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fortunately, Halloween can’t be scarier than any other day this year. So grab your pillow case and stuff it with treats from the great Drug Channels pumpkin patch: Spooky! PBMs are conjuring a terrifying number of formulary exclusions for oncology drugs Eerie! Brrr.did you hear that? It’s the biosimilar boom! Creepy! Scream as Blue Cross Blue Shield frightfully overpays hospitals Shocking!
Merck known as MSD outside the United States and Canada, moment blazoned that it has withdrawn its Premerger Announcement and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “ HSR Act”), in connection with Merck’s pending accession of Acceleron PharmaInc. (Nasdaq XLRN). As preliminarily blazoned on October 12, 2021, Merck commenced, through a attachment, Astros Merger Sub,Inc., a cash tender offer to buy all outstanding shares of common stock of Accele
One of the most common tasks in Cheminformatics is exploratory data analysis (EDA). Given a new dataset, we often need to rapidly explore the chemistry in a set containing hundreds, or even thousands, of molecules. One useful technique for EDA is the Bemis-Murcko framework. This technique, originally published by Guy Bemis and Mark Murcko, provides a simple but elegant means of grouping molecules.
Annual Drug Patent Expirations for HYSINGLA+ER Hysingla Er is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from one supplier. There are…. The post New patent expiration for Purdue Pharma drug HYSINGLA ER appeared first on DrugPatentWatch - Make Better Decisions.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Since the World Health Organization (WHO) declared the novel coronavirus (COVID-19) outbreak a global pandemic on March 11, 2020, researchers around the world have been working tirelessly to discover effective preventive treatments and therapeutic agents. Currently, the FDA has only approved one drug, Veklury (remdesivir), for treatment of COVID-19.
PfizerInc. and BioNTech moment blazoned that theU.S. Food and Drug Administration (FDA) has authorized for exigency use the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 times of age ( also appertained to as 5 to< 12 times). For this age group, the vaccine is to be administered in a two- cure authority of 10-µg boluses given 21 days piecemeal.
Recently it was reported that the President Biden appears ready to nominate former FDA Commissioner Robert Califf to boomerang back and head the agency for a second time. If so, he returns to very different circumstances than when he left FDA in January 2017 after an 11-month stay. While FDA is accustomed to controversy while making difficult decisions, lately, it is much more than that.
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Spain. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Spain? appeared first on DrugPatentWatch - Make Better Decisions.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Lower talk, further action New report patronized by ViiV Healthcare provides roadmap to achieve health equity by 2040. ViiV Healthcare blazoned the release of Achieving health equity a roadmap to barring difference, a new report conducted by Economist Impact, a division of The Economist Group, that explores the openings that could be created by barring health difference in the UK and US over the coming 20 times, while charting a bold course for unified action.
PFIZER AND BIONTECH TO GiveU.S. GOVERNMENT AN Fresh 50 MILLION PEDIATRIC Boluses OF COVID-19 VACCINE TO SUPPORT Farther PREPAREDNESS FOR FUTURE NEEDS. PfizerInc. (NYSE PFE) and BioNTech SE (Nasdaq BNTX) moment blazoned that theU.S. government has bought 50 million further boluses of the companies’COVID-19 vaccine. TheU.S. will admit these fresh boluses to continue to support preparedness for pediatric vaccinations, including securing vaccines for children under 5 times of age, should they admit
ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be enforced successfully in a variety of European healthcare settings. ViiV Healthcare, the global specialist HIV company maturity possessed by GlaxoSmithKline plc (“ GSK”), with PfizerInc. and Shionogi Limited as shareholders, moment presented positive interim data from the CARISEL (Cabotegravir and Rilpivirine Perpetration Study in European Locales) study, which was initiated and condu
New analysis from the Phase III FIGARO-DKD study will be presented, which investigated the impact of finerenone on renal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) / A subgroup analysis from FIDELITY, a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, will be presented, which investigated the impact of finerenone on renal outcomes on top of standard of care / Additional finerenone data from the FIDELIO-DKD study and the pooled analysis FIDELITY wi
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) announced that its Board of Directors resolved today to engage in the acquisition of its own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act of Japan, as detailed below. “At our current share price, we see an opportunity to buy back our shares at a substantial discount to what we perceive is their underlying value,” said Costa Saroukos, directo
Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER ( 1). Q3 2021 sales grew double digit to €10.4 billion (up 10.1%) due to strong growth from Dupixent ® , Vaccines and CHC. Specialty Care deals increased20.2 with strong donation from Dupixent ® (54.6 to€ million).Vaccines up16.5, with record daily deals driven by discerned flu vaccines and meningitis ballot recovery.
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Romania. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Romania? appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for ERLEADA Erleada is a drug marketed by Janssen Biotech and is included in one NDA. It is available from one supplier. There are nine patents…. The post New patent for Janssen Biotech drug ERLEADA appeared first on DrugPatentWatch - Make Better Decisions.
– This Clinical Study is the First from Merck and Gilead’s Collaboration to Develop Potential Long-Acting HIV Treatment Options –. Gilead Lores, and Merck, known as MSD outside the United States and Canada, moment blazoned the launch of a Phase 2 clinical study assessing an investigational formerly-daily oral combination treatment authority of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral remedy. “ Hookups and collaborations are critical
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
113 
Let's personalize your content